THinc advises clients on how to efficiently and rapidly bring new products to market and teams with our clients to implement these drug development strategies. Our company includes regulatory affairs, medical writing, clinical operations, and nonclinical safety professionals each with 10 to 30 years of pharmaceutical experience.
THinc has a history of successful client partnerships demonstrated through collaboration on more than 20 new drug applications (NDAs) and nearly 60 new molecular entity (NME) or novel formulation development programs. We tailor our services to meet client needs from the
pre-Investigational New Drug application (IND) stage to product registration. Our clientele ranges from emerging, privately held biopharmaceutical companies to Fortune 500 pharmaceutical companies.
Established as a privately held consulting firm in 1995, THinc is located in the heart of the biotechnology industry in the San Francisco Bay Area.
Our regulatory affairs professionals are well-positioned to advise and collaborate with clients on drug-development strategies and execution in the areas of clinical, nonclinical, and chemistry, manufacturing, and controls (CMC).
Our medical and scientific writers have extensive experience in producing on-time, high-quality regulatory documents to support drug-development programs from pre-IND through Phase 4.
Our nonclinical safety professionals possess a wealth of experience in planning, analysis, and interpretation of nonclinical studies and in integrating the nonclinical findings into the clinical program.